Table 2.

Adjusted Rate Ratios (RRs) for Meningioma, Glioma, and Any CNS SN^a

	Meningioma (n = 146)			Glioma (n = 53)			Any CNS SN (n = 212)
	RR	95% CI	P Value	RR	95% CI	P Value	RR	95% CI	P Value
Growth hormone treatment
No	1		.61	1		.21	1		.94
Yes	0.8	0.4–1.7		1.9	0.7–4.8		1.0	0.6–1.8
Sex
Male	1		<.001	1		.79	1		.002
Female	1.8	1.3–2.6		0.9	0.5–1.7		1.6	1.2–2.2
Age at primary cancer diagnosis, y
≥15	1		<.001	1		.22	1		<.001
0–4	4.8	2.1–11.0		2.0	0.5–7.8		4.8	2.4–9.7
5–9	2.6	1.2–5.5		0.9	0.2–3.5		2.5	1.3–4.7
10–14	1.2	0.6–2.6		1.8	0.6–5.6		1.7	0.9–3.0
CRT/time between cranial radiation and CNS SN
No CRT	1		<.001	1		<.001	1		<.001
CRT ≤45 Gy and <10 y	0.0	0.0–6.7		7.9	2.7–23.0		9.5	4.3–20.8
CRT ≤45 Gy and 10–19 y	23.1	9.9–53.7		4.1	1.5–11.3		11.1	6.3–19.5
CRT ≤45 Gy and ≥20 y	22.0	9.7–50.2		1.5	0.3–6.3		9.9	5.5–17.5
CRT >45 Gy and <10 y	55.1	15.3–198.1		13.5	4.0–46.1		23.9	10.2–55.9
CRT >45 Gy and 10–19 y	47.3	19.4–115.2		13.4	4.8–37.6		24.9	13.6–45.8
CRT >45 Gy and ≥20 y	58.5	25.5–134.2		10.7	3.1–36.7		25.3	14.0–46.0
Intrathecal methotrexate
No	1		.3	1		.39	1		.29
Yes	1.3	0.8–2.0		1.3	0.8–2.0		1.3	0.8–2.0
Estrogen and/or progesterone
No	1		.19	1		.71	1		.09
Yes	0.7	0.5–1.2		0.7	0.5–1.2		0.7	0.5–1.2
Alkylating agent
No	1		.03	1		.65	1		.08
Yes	0.7	0.5–1.0		0.7	0.5–1.0		0.7	0.5–1.0

^aAdjusted for age at follow-up.